text: The mainstay of treatment  for gastrointestinal<unk>  tumor (GIST) is surgical resection. Medical therapy with tyrosine kinase inhibitors are indicated in patients with unresectable lesions, to decrease tumor size prior to surgery and for prevention of recurrent disease. Imatinib 400 mg to 800 mg PO q24h is the drug of choice for patients with aforementioned conditions. Patients resistant to imatinib are treated with sunitinib 50 mg PO q24h. Medical therapy such as fluid resuscitation, antibiotics cover, deep venous thrombosis prophylaxis should also be given to decrease perioperative morbidity associated with resection of GIST.
option_0: Gastrointestinal stromal tumor medical therapy
option_1: Gastrointestinal stromal tumor surgery
option_2: Esthesioneuroblastoma medical therapy
option_3: Atypical teratoid rhabdoid tumor medical therapy
option_4: Mesothelioma medical therapy
option_5: Acinic cell carcinoma medical therapy
option_6: Hepatic hemangioma medical therapy
option_7: Hepatoblastoma medical therapy